Boni V, Fidler MJ, Arkenau HT, Spira A, et al. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res 2022;28:2020-2029.
PMID: 35165101